January 20, 2020
Takao Inoue, Oligonucleotide Therapeutics Section Head, NIH’s Division of Molecular Target and Gene Therapy Products Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space in recent years, which have...read more